Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2020-03-19 Notice of Dividend Amou…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.40 per share (news with additional features)
Notice of Dividend Amount Classification · 99% confidence The document text explicitly mentions 'Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend'. It details the outcomes of the Annual General Meeting (AGM), including the approval of the dividend and the election/re-election of board members. This content directly aligns with the definition of AGM Information (AGM-R). Although it mentions dividend approval, the primary focus is the meeting's results and governance changes, making AGM-R the most specific fit over DIV or CGR. It is not a full 10-K, an ER, or a simple RPA, as it contains substantive details about the meeting's resolutions.
2020-03-19 English
DGAP-DD: BB BIOTECH AG english
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and the subheading "Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them". It details a transaction (Disposal) by an individual identified as a 'Member of the administrative or supervisory body' of BB BIOTECH AG, including the instrument type (Share), price, and volume. This directly matches the definition for Director's Dealing.
2020-03-03 English
BB Biotech AG publishes its 2019 annual report (news with additional features)
Report Publication Announcement Classification · 99% confidence The document is titled "BB Biotech AG publishes its 2019 annual report (news with additional features)" and explicitly states, "BB Biotech AG published its annual report for fiscal year 2019 today." It contains key financial highlights (total share return, net gain/loss) and mentions the audited consolidated financial statements are included in the report. However, the document itself is a short news release announcing the availability of the full report, as evidenced by the line: "BB Biotech’s annual report 2019 can be downloaded at [www.bbbiotech.com]". According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement pointing to the full document should be classified as a Report Publication Announcement (RPA). While the content relates to the Annual Report (10-K), the format is that of an announcement of publication.
2020-02-21 English
Annual financial report 2019
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2019' and contains comprehensive financial data, including consolidated financial statements, notes to the financial statements, auditor reports, and management commentary for the fiscal year 2019. It covers company activity, performance metrics, and governance, fitting the definition of an Annual Report (10-K). FY 2019
2020-02-21 German
BB Biotech AG closes the 2019 fiscal year with a profit
Earnings Release Classification · 100% confidence The document is dated January 17, 2020, and is titled 'BB Biotech AG closes the 2019 fiscal year with a profit'. It explicitly states it is releasing information about its results for the fiscal year 2019 based on 'preliminary unaudited consolidated results'. It mentions a profit figure (CHF 677 million) and notes that the 'complete annual report will be published on February 21, 2020'. This structure—releasing preliminary, key financial highlights before the full report—is characteristic of an Earnings Release (ER). It is not the full 10-K, nor is it a transcript (CT) or a general announcement of a report publication (RPA), as it contains the actual preliminary results. FY 2019
2020-01-17 English
BB BIOTECH AG: Expansion of the Board of Directors
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc' announcement dated November 20, 2019, titled 'BB BIOTECH AG: Expansion of the Board of Directors'. The core content details the nomination of two new members (Susan Galbraith and Mads Krogsgaard Thomsen) for election to the Board of Directors at the upcoming Annual General Meeting (AGM) on March 19, 2020, and the non-re-election of an existing member. This directly concerns changes in the company's governing body and senior personnel. This aligns perfectly with the definition for Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (PSI), but a specific announcement about board composition.
2019-11-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.